On March 20, 2023 The management team of Transcenta Holding Limited (06628.HK) reported that it will attend the 2022 annual results release conference call on March 31, 2023 (Press release, Transcenta, MAR 20, 2023, View Source [SID1234629064]). Transcenta is a clinical stage biopharmaceutical company with fully integrated capabilities in the discovery, research, development and manufacture of antibodies-based therapeutics.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Meeting Details:
MeetingDate:
Friday, March 31, 2023
Meeting time:
10:00 a.m. (Beijing time)
Meeting Language:
English
Attendance Management:
Dr. Xueming Qian, Chief Executive Officer
Dr. Caroline Germa, EVP, Global Medicine Development and CMO
Mr. Daniel Weng, EVP, CFO
Ms. Vivian Wang, VP, Investor Relations & Capital Markets, Board Secretary
Enrollment form:
Please scan the QR code to register
(please register before March 27, 2023)